Hormone therapy and thromboembolic disease.
Hemostasis and thrombosis Current Opinion in Hematology. 14(5):488-493, September 2007.
Battaglioli, Tullia; Martinelli, Ida
Abstract:
Purpose of review:
Hormone therapy increases the risk of venous thromboembolism (VTE). To reduce this risk, changes in dosage, composition and route of administration have been made over the years. This review provides a summary of the available evidence and an update on the most recent findings on the issue.
Recent findings:
Contraceptives containing third-generation progestagens confer a higher risk of VTE than second-generation compounds. Little data are available on preparations containing less than 30 [mu]g of estrogen, new progestagens or levonorgestrel-releasing intrauterine devices. Hormone replacement therapy increases the risk of VTE by 2 to 3-fold. Transdermal administration may be less thrombogenic than oral administration, while different estrogens and progestagens may carry a different risk. VTE risk is further increased in carriers of inherited thrombophilia. Despite a similar increase in relative risk of thrombosis associated with hormone therapy, absolute risk is lower in fertile women and higher in postmenopausal ones. Universal screening for thrombophilia before prescribing hormone replacement therapy might be cost-effective.
Summary:
Careful evaluation of individual risk factor is warranted before prescribing hormone therapy. Further investigations are needed to establish whether or not newer compounds are safer than older ones with respect to the risk of thrombosis.
Showing posts with label Hormone Replacement Therapy. Show all posts
Showing posts with label Hormone Replacement Therapy. Show all posts
Sunday, August 26, 2007
Wednesday, August 22, 2007
Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease.[Miscellaneous]
Author
Mohandas, Bhavna; Mehta, Jawahar L
Institution
Division of Cardiovascular Medicine, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Title
Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease.[Miscellaneous]
Source
Current Opinion in Cardiology. 22(5):434-442, September 2007.
Abstract
Purpose of review: Coronary heart disease in women is a common cause of morbidity and mortality, particularly after menopause. It was thought that estrogen and progesterone protected women from coronary heart disease. The recommendations of the recent Women's Health Initiative, however, are that hormone replacement therapy should not be used for primary prevention of coronary heart disease in women.
Here, we have made a comprehensive review of major studies and comment on the validity of this recommendation.
We have also analyzed the importance of dietary modification in primary prevention. In addition, we have delineated the important predictors of cardiovascular disease in women from prior observational and clinical studies.
Recent findings: Recent major studies, including the Women's Health Initiative (WHI) and Heart and Estrogen/Progestin Replacement Study (HERS), studied the role of hormone replacement therapy in protecting women from coronary heart disease. These studies showed no significant reduction in coronary heart disease events. In addition, the dietary modification component of the Women's Health Initiative did not show any significant reduction in the incidence of coronary heart disease.
Summary: It can be summarized that hormone replacement is not generally recommended in postmenopausal women for primary prevention of coronary heart disease.
Although the dietary modification trials did not show any significant reduction in the incidence of coronary heart disease, it is currently recommended to continue using a heart-healthy diet.
Mohandas, Bhavna; Mehta, Jawahar L
Institution
Division of Cardiovascular Medicine, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Title
Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease.[Miscellaneous]
Source
Current Opinion in Cardiology. 22(5):434-442, September 2007.
Abstract
Purpose of review: Coronary heart disease in women is a common cause of morbidity and mortality, particularly after menopause. It was thought that estrogen and progesterone protected women from coronary heart disease. The recommendations of the recent Women's Health Initiative, however, are that hormone replacement therapy should not be used for primary prevention of coronary heart disease in women.
Here, we have made a comprehensive review of major studies and comment on the validity of this recommendation.
We have also analyzed the importance of dietary modification in primary prevention. In addition, we have delineated the important predictors of cardiovascular disease in women from prior observational and clinical studies.
Recent findings: Recent major studies, including the Women's Health Initiative (WHI) and Heart and Estrogen/Progestin Replacement Study (HERS), studied the role of hormone replacement therapy in protecting women from coronary heart disease. These studies showed no significant reduction in coronary heart disease events. In addition, the dietary modification component of the Women's Health Initiative did not show any significant reduction in the incidence of coronary heart disease.
Summary: It can be summarized that hormone replacement is not generally recommended in postmenopausal women for primary prevention of coronary heart disease.
Although the dietary modification trials did not show any significant reduction in the incidence of coronary heart disease, it is currently recommended to continue using a heart-healthy diet.
Friday, August 10, 2007
Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease
Author
Mohandas, Bhavna; Mehta, Jawahar L
Institution
Division of Cardiovascular Medicine, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Title
Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease.[Miscellaneous]
Source
Current Opinion in Cardiology. 22(5):434-442, September 2007.
Abstract
Purpose of review: Coronary heart disease in women is a common cause of morbidity and mortality, particularly after menopause. It was thought that estrogen and progesterone protected women from coronary heart disease. The recommendations of the recent Women's Health Initiative, however, are that hormone replacement therapy should not be used for primary prevention of coronary heart disease in women. Here, we have made a comprehensive review of major studies and comment on the validity of this recommendation. We have also analyzed the importance of dietary modification in primary prevention. In addition, we have delineated the important predictors of cardiovascular disease in women from prior observational and clinical studies.
Recent findings: Recent major studies, including the Women's Health Initiative (WHI) and Heart and Estrogen/Progestin Replacement Study (HERS), studied the role of hormone replacement therapy in protecting women from coronary heart disease. These studies showed no significant reduction in coronary heart disease events. In addition, the dietary modification component of the Women's Health Initiative did not show any significant reduction in the incidence of coronary heart disease.
Summary: It can be summarized that hormone replacement is not generally recommended in postmenopausal women for primary prevention of coronary heart disease. Although the dietary modification trials did not show any significant reduction in the incidence of coronary heart disease, it is currently recommended to continue using a heart-healthy diet.
Mohandas, Bhavna; Mehta, Jawahar L
Institution
Division of Cardiovascular Medicine, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Title
Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease.[Miscellaneous]
Source
Current Opinion in Cardiology. 22(5):434-442, September 2007.
Abstract
Purpose of review: Coronary heart disease in women is a common cause of morbidity and mortality, particularly after menopause. It was thought that estrogen and progesterone protected women from coronary heart disease. The recommendations of the recent Women's Health Initiative, however, are that hormone replacement therapy should not be used for primary prevention of coronary heart disease in women. Here, we have made a comprehensive review of major studies and comment on the validity of this recommendation. We have also analyzed the importance of dietary modification in primary prevention. In addition, we have delineated the important predictors of cardiovascular disease in women from prior observational and clinical studies.
Recent findings: Recent major studies, including the Women's Health Initiative (WHI) and Heart and Estrogen/Progestin Replacement Study (HERS), studied the role of hormone replacement therapy in protecting women from coronary heart disease. These studies showed no significant reduction in coronary heart disease events. In addition, the dietary modification component of the Women's Health Initiative did not show any significant reduction in the incidence of coronary heart disease.
Summary: It can be summarized that hormone replacement is not generally recommended in postmenopausal women for primary prevention of coronary heart disease. Although the dietary modification trials did not show any significant reduction in the incidence of coronary heart disease, it is currently recommended to continue using a heart-healthy diet.
Subscribe to:
Posts (Atom)